数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Lai Ling Tam Director and Executive Chairman 57 未披露 未持股 2021-04-14
Si Zong Wu Director 68 未披露 未持股 2021-04-14
Aiping Lyu Director 57 未披露 未持股 2021-04-14
Peter R. Kellogg Director 78 9.93万美元 736.68 2021-04-14
Wing Yan Lo Director 60 10.17万美元 未持股 2021-04-14
Mark Waslen Director 60 10.25万美元 11.50 2021-04-14

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jiabiao Wang Chief Executive Officer 37 未披露 未持股 2021-04-14
Terrence Lu Chief Financial Officer 31 未披露 未持股 2021-04-14

董事简历

中英对照 |  中文 |  英文
Lai Ling Tam

Lai Ling Tam目前是Kaisa Group的高级顾问,自2015年以来一直担任该职位。Tam博士主要负责为该集团制定投资和融资策略。在此之前,他于2010年至2014年担任Kaisa集团副董事长兼执行董事。从2007年12月至2008年11月,Tam博士曾担任SPG Land(Holdings)Limited的执行董事,负责公司融资活动和公司的投资者关系。从2005年4月至2007年11月,谭博士曾担任合生发展控股有限公司的副董事总经理兼首席财务官,负责制定和执行公司的融资战略。Tam博士亦曾担任青岛啤酒股份有限公司的独立非执行董事。从1998年3月至2005年4月,Tam博士在ICEA Capital Limited工作了7年。他的最后一个职位是其投资银行部的董事总经理,在此期间,他执行了各种公司融资交易,包括并购,债务和股权融资。在此之前,Tam博士还曾在企业融资领域的大型国际投资银行工作,以及在业务发展领域的一家跨国石油公司工作。 Tam博士拥有伦敦大学学院的工程学学士学位和剑桥大学的博士学位。他还是特许金融分析师的持有人。


Lai Ling Tam has been our Executive Chairman of the Board of Directors since September 2020. He has served as a senior advisor to Kaisa Group 1638.HK since 2015 where he is primarily responsible for advising on investment and financing strategies. Prior to that, he was the Vice Chairman and Executive Director of Kaisa between 2010 and 2014. Prior to joining Kaisa Group, Dr. Tam was a senior executive and a member of the board of a number of leading China-based real estate developers and international investment banks. From December 2007 to November 2008 Dr. Tam was an executive director of SPG Land (Holdings) where he supervised corporate finance activities and investor relations. From April 2005 to November 2007 he was the deputy managing director and chief financial officer of Hopson Development (754.HK), where he was responsible for formulating and executing financing strategies. Dr. Tam has also served as an independent non-executive director of Tsingtao Brewery Company (168.HK). From March 1998 to April 2005 Dr. Tam worked for ICEA Capital Limited with his last position as a managing director of the investment banking division, during which he executed a wide variety of corporate finance transactions, including M&A, and debt and equity financings. Prior to that, he worked for major international investment banks in the area of corporate finance, as well as a multi-national oil company in the area of business development. Dr. Tam received his bachelor’s degree in Engineering from University College London, and a Ph.D. from the University of Cambridge. He is also a holder of Chartered Financial Analyst.
Lai Ling Tam目前是Kaisa Group的高级顾问,自2015年以来一直担任该职位。Tam博士主要负责为该集团制定投资和融资策略。在此之前,他于2010年至2014年担任Kaisa集团副董事长兼执行董事。从2007年12月至2008年11月,Tam博士曾担任SPG Land(Holdings)Limited的执行董事,负责公司融资活动和公司的投资者关系。从2005年4月至2007年11月,谭博士曾担任合生发展控股有限公司的副董事总经理兼首席财务官,负责制定和执行公司的融资战略。Tam博士亦曾担任青岛啤酒股份有限公司的独立非执行董事。从1998年3月至2005年4月,Tam博士在ICEA Capital Limited工作了7年。他的最后一个职位是其投资银行部的董事总经理,在此期间,他执行了各种公司融资交易,包括并购,债务和股权融资。在此之前,Tam博士还曾在企业融资领域的大型国际投资银行工作,以及在业务发展领域的一家跨国石油公司工作。 Tam博士拥有伦敦大学学院的工程学学士学位和剑桥大学的博士学位。他还是特许金融分析师的持有人。
Lai Ling Tam has been our Executive Chairman of the Board of Directors since September 2020. He has served as a senior advisor to Kaisa Group 1638.HK since 2015 where he is primarily responsible for advising on investment and financing strategies. Prior to that, he was the Vice Chairman and Executive Director of Kaisa between 2010 and 2014. Prior to joining Kaisa Group, Dr. Tam was a senior executive and a member of the board of a number of leading China-based real estate developers and international investment banks. From December 2007 to November 2008 Dr. Tam was an executive director of SPG Land (Holdings) where he supervised corporate finance activities and investor relations. From April 2005 to November 2007 he was the deputy managing director and chief financial officer of Hopson Development (754.HK), where he was responsible for formulating and executing financing strategies. Dr. Tam has also served as an independent non-executive director of Tsingtao Brewery Company (168.HK). From March 1998 to April 2005 Dr. Tam worked for ICEA Capital Limited with his last position as a managing director of the investment banking division, during which he executed a wide variety of corporate finance transactions, including M&A, and debt and equity financings. Prior to that, he worked for major international investment banks in the area of corporate finance, as well as a multi-national oil company in the area of business development. Dr. Tam received his bachelor’s degree in Engineering from University College London, and a Ph.D. from the University of Cambridge. He is also a holder of Chartered Financial Analyst.
Si Zong Wu

Si Zong Wu,自1997年起任同济大学教授,博士生导师。兼任同济大学经济管理学院党委书记,副院长。吴教授是上海市场营销学会副会长,中国市场营销学会常务理事。吴教授讲授经济学和国际贸易。他的主要研究领域包括企业管理,市场营销和国际贸易。1994年至1997年,任江西财经大学国际贸易学院事务委员会主任。从2001年到2008年,吴教授发表了多篇论文,并参与了他的专业领域的各种研究项目。2000年至2007年,他还出版了各种市场营销,商业和贸易书籍。吴教授于1982年获得江西财经大学经济学学士学位。1995年获上海财经大学经济学硕士学位。吴教授兼任Shanghai Guanzong Investment Management Co., Ltd执行董事兼总经理,Shanghai Shimao Co., Ltd.独立董事,上海证券交易所股票代码:600823。AnHui Higasket Plastics Co., Ltd.Top Spring International Holdings Ltd.的独立非执行董事(香港联交所股票代码:2688)及Chitina Holding Ltd.(TPE:4137)董事,Ningbo HOBOS Energy Conservation and Technology Co., Ltd.(NEEQ:830954)及Huajiang Holding Co., Ltd.(NEEQ:430634)董事。


Si Zong Wu has served on our Board of Directors since June 2019 and is the Chairman of our audit committee and a member of our compensation committee and nominating and corporate governance committee. Professor Wu is a professor and a doctoral tutor at Tongji University since 1997. He served as the Secretary of the Party Committee and the vice dean of the Economic and Management School of Tongji University. Professor Wu is the vice president of Shanghai Marketing Society and the standing director of China Marketing Society. Professor Wu lectures in economics and international trade. His main research fields include business management, marketing and international trade. From 1994 to 1997 he was the head of affairs committee of the International Trade Faculty at Jiangxi University of Finance and Economics. From 1982 to 2008 Professor Wu published several theses and was involved in various research projects in his fields of expertise. He also published various books in marketing, commerce and trade from 2001 to 2020. Professor Wu received his bachelor degree in Economics from Jiangxi University of Finance and Economics in 1982. In 1995 he received his master degree in Economics at Shanghai University of Finance and Economics. Professor Wu is the executive director and general manager of Shanghai Guanzong Investment Management Co., Ltd.; independent director of Shanghai Shimao Co., Ltd. SSE: 600823 and AnHui Higasket Plastics Co., Ltd.; independent non-executive director of Top Spring International Holdings Ltd. (SEHK: 2688); and director of Chitina Holding Ltd. (TPE: 4137).
Si Zong Wu,自1997年起任同济大学教授,博士生导师。兼任同济大学经济管理学院党委书记,副院长。吴教授是上海市场营销学会副会长,中国市场营销学会常务理事。吴教授讲授经济学和国际贸易。他的主要研究领域包括企业管理,市场营销和国际贸易。1994年至1997年,任江西财经大学国际贸易学院事务委员会主任。从2001年到2008年,吴教授发表了多篇论文,并参与了他的专业领域的各种研究项目。2000年至2007年,他还出版了各种市场营销,商业和贸易书籍。吴教授于1982年获得江西财经大学经济学学士学位。1995年获上海财经大学经济学硕士学位。吴教授兼任Shanghai Guanzong Investment Management Co., Ltd执行董事兼总经理,Shanghai Shimao Co., Ltd.独立董事,上海证券交易所股票代码:600823。AnHui Higasket Plastics Co., Ltd.Top Spring International Holdings Ltd.的独立非执行董事(香港联交所股票代码:2688)及Chitina Holding Ltd.(TPE:4137)董事,Ningbo HOBOS Energy Conservation and Technology Co., Ltd.(NEEQ:830954)及Huajiang Holding Co., Ltd.(NEEQ:430634)董事。
Si Zong Wu has served on our Board of Directors since June 2019 and is the Chairman of our audit committee and a member of our compensation committee and nominating and corporate governance committee. Professor Wu is a professor and a doctoral tutor at Tongji University since 1997. He served as the Secretary of the Party Committee and the vice dean of the Economic and Management School of Tongji University. Professor Wu is the vice president of Shanghai Marketing Society and the standing director of China Marketing Society. Professor Wu lectures in economics and international trade. His main research fields include business management, marketing and international trade. From 1994 to 1997 he was the head of affairs committee of the International Trade Faculty at Jiangxi University of Finance and Economics. From 1982 to 2008 Professor Wu published several theses and was involved in various research projects in his fields of expertise. He also published various books in marketing, commerce and trade from 2001 to 2020. Professor Wu received his bachelor degree in Economics from Jiangxi University of Finance and Economics in 1982. In 1995 he received his master degree in Economics at Shanghai University of Finance and Economics. Professor Wu is the executive director and general manager of Shanghai Guanzong Investment Management Co., Ltd.; independent director of Shanghai Shimao Co., Ltd. SSE: 600823 and AnHui Higasket Plastics Co., Ltd.; independent non-executive director of Top Spring International Holdings Ltd. (SEHK: 2688); and director of Chitina Holding Ltd. (TPE: 4137).
Aiping Lyu

Aiping Lyu自2012年2月起担任香港浸会大学中医学院院长教授及院长。他是香港中医药发展委员会成员,香港研究资助委员会生物学小组的成员。他目前还是中国药典委员会成员。Lyu博士一直专注于中医的转化研究,包括对类风湿关节炎的药理和临床评价以及中医模式的诊断和干预,以及基于中药的新药的开发。Lyu博士还积极参与中医药标准化研究和中国中医药发展战略规划研究。自2009年以来,Lyu博士被任命为中国国际标准化组织ISO/TC249技术委员会中国代表团团长。多年来,Lyu博士从他的研究活动中获得了60多项专利,并出版了30多本书和500多篇文章。Lyu博士于1983年获得江西中医药大学学士学位,并在北京中国中医科学院(现称中国中医科学院)获得硕士和博士学位。Lyu博士自2018年3月起担任Kaisa Health Group Holdings Limited(香港联交所股票代码:876)的独立非执行董事。


Aiping Lyu has served on our Board of Directors since June 2019 and is a member of our audit committee, compensation committee and nominating and corporate governance committee. Professor Lyu has been the Chair Professor and Dean of School of Chinese Medicine of Hong Kong Baptist University since February 2012. He is a member of the Chinese Medicine Development Committee in Hong Kong and a member of Biology and Medicine Panel of The Research Grants Council in Hong Kong. He also currently serves as a member of the Chinese Pharmacopoeia Commission of the People’s Republic of China. Professor Lyu had been focused on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with traditional Chinese medicine pattern diagnosis and interventions, and development of new drugs based on Chinese medicines. Professor Lyu is also actively involved in the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China. Since 2009 Professor Lyu has been appointed as the head of the Chinese Delegation in the Technical Committee of the International Organization for Standardization on traditional Chinese medicine ISO/TC249. Over the years, Professor Lyu has obtained more than 60 patents from his research activities and published more than 30 books and over 500 articles. Professor Lyu obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983 and further obtained his master and PhD degrees in the China Academy of Traditional Chinese Medicine in Beijing (presently known as the China Academy of Chinese Medical Sciences). Professor Lyu has served as an independent non-executive director of Kaisa Health Group Holdings Limited (SEHK: 876) since March 2018.
Aiping Lyu自2012年2月起担任香港浸会大学中医学院院长教授及院长。他是香港中医药发展委员会成员,香港研究资助委员会生物学小组的成员。他目前还是中国药典委员会成员。Lyu博士一直专注于中医的转化研究,包括对类风湿关节炎的药理和临床评价以及中医模式的诊断和干预,以及基于中药的新药的开发。Lyu博士还积极参与中医药标准化研究和中国中医药发展战略规划研究。自2009年以来,Lyu博士被任命为中国国际标准化组织ISO/TC249技术委员会中国代表团团长。多年来,Lyu博士从他的研究活动中获得了60多项专利,并出版了30多本书和500多篇文章。Lyu博士于1983年获得江西中医药大学学士学位,并在北京中国中医科学院(现称中国中医科学院)获得硕士和博士学位。Lyu博士自2018年3月起担任Kaisa Health Group Holdings Limited(香港联交所股票代码:876)的独立非执行董事。
Aiping Lyu has served on our Board of Directors since June 2019 and is a member of our audit committee, compensation committee and nominating and corporate governance committee. Professor Lyu has been the Chair Professor and Dean of School of Chinese Medicine of Hong Kong Baptist University since February 2012. He is a member of the Chinese Medicine Development Committee in Hong Kong and a member of Biology and Medicine Panel of The Research Grants Council in Hong Kong. He also currently serves as a member of the Chinese Pharmacopoeia Commission of the People’s Republic of China. Professor Lyu had been focused on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with traditional Chinese medicine pattern diagnosis and interventions, and development of new drugs based on Chinese medicines. Professor Lyu is also actively involved in the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China. Since 2009 Professor Lyu has been appointed as the head of the Chinese Delegation in the Technical Committee of the International Organization for Standardization on traditional Chinese medicine ISO/TC249. Over the years, Professor Lyu has obtained more than 60 patents from his research activities and published more than 30 books and over 500 articles. Professor Lyu obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983 and further obtained his master and PhD degrees in the China Academy of Traditional Chinese Medicine in Beijing (presently known as the China Academy of Chinese Medical Sciences). Professor Lyu has served as an independent non-executive director of Kaisa Health Group Holdings Limited (SEHK: 876) since March 2018.
Peter R. Kellogg

Peter R. Kellogg, 自2000年起担任公司董事。2000年矛利兹凯洛格(美国一家注册经纪交易商以及纽约证交所专家公司)和高盛集团合并,在此之前他曾担任该公司高级总经理。现任公司薪酬委员会以及提名委员会成员;他也是齐格勒公司和美国滑雪队成员。


Peter R. Kellogg has served on our Board of Directors since June 2000 and is a member of our audit committee, compensation committee and nominating and corporate governance committee. Mr. Kellogg was a senior managing director of Spear, Leeds & Kellogg, a registered broker-dealer in the United States and a specialist firm on the NYSE until the firm merged with Goldman Sachs in 2000. Mr. Kellogg is also a member of the board of the Ziegler Companies and the U.S. Ski Team.
Peter R. Kellogg, 自2000年起担任公司董事。2000年矛利兹凯洛格(美国一家注册经纪交易商以及纽约证交所专家公司)和高盛集团合并,在此之前他曾担任该公司高级总经理。现任公司薪酬委员会以及提名委员会成员;他也是齐格勒公司和美国滑雪队成员。
Peter R. Kellogg has served on our Board of Directors since June 2000 and is a member of our audit committee, compensation committee and nominating and corporate governance committee. Mr. Kellogg was a senior managing director of Spear, Leeds & Kellogg, a registered broker-dealer in the United States and a specialist firm on the NYSE until the firm merged with Goldman Sachs in 2000. Mr. Kellogg is also a member of the board of the Ziegler Companies and the U.S. Ski Team.
Wing Yan Lo

Wing Yan Lo,自2003年7月起担任董事会成员,并担任薪酬委员会和提名/公司治理委员会主席以及审计委员会主席。Lo博士是TMT(技术,媒体和电信)和消费领域的资深管理人员。他曾在中国联通,香港电信,香港花旗银行、I.T. Limited和South China Media Group等公司担任高级职位。他目前是SMI Holdings Group Ltd.(香港联交所股票代码:0198)的执行主席,该集团是中国最大的电影和新零售连锁店之一。他还是Captcha Media Ltd.(一家数字营销和战略机构)的主席,以及新的零售咨询平台OtoO Academy Limited&Strategenes Limited,一家香港的金融和战略咨询公司的主席。Lo博士毕业于剑桥大学,获得了硕士学位,药理学学位和80年代分子神经科学博士学位。Lo博士目前担任多家香港上市公司的独立非执行董事,包括Television Broadcasts Ltd.(香港联交所股票代码:511),CSI Properties Ltd.(香港联交所股票代码:497),SITC International Limited(香港联合交易所代码: 1308),Jing Rui Holdings Limited(香港联交所股票代码:1862),Ronshine China Holdings Limited(香港联交所股票代码:3301)及Hsin Chong Group Holdings Limited(香港联交所股票代码:0404)。Lo博士还是Charles K. Kao阿尔茨海默病基金会和ISF学院的创始理事,以及现任青年成就香港分会主席。Lo博士现为数码港顾问小组成员及香港红十字会输血服务医院管理委员会成员。1998年,Lo博士被任命为香港和平大法官。2003年至2016年,他被任命为汕头市人民政治协商会议委员。Lo博士目前担任提名/公司治理委员会和薪酬委员会主席。


Wing Yan Lo has served on our Board of Directors since July 2003 and is the chairman of our compensation committee and nominating and corporate governance committee. Dr. Lo is an experienced executive in the TMT technology, media and telecommunications and consumer sectors. He has previously held senior positions at China Unicom, Hongkong Telecom, Citibank HK, I.T. Limited, South China Media Group and Kidsland International Holdings Limited. He is currently the chairman of Captcha Media Ltd., a digital marketing and strategy agency. Dr. Lo graduated from Cambridge University with a M.Phil. degree in Pharmacology and a Ph.D. degree in Molecular Neuroscience in the 80’s. Dr. Lo currently serves as an independent non-executive director of a number of publicly listed companies in Hong Kong, including Television Broadcasts Ltd. (SEHK: 511), CSI Properties Ltd. (SEHK: 497), Jing Rui Holdings Limited (SEHK:1862) and South Shore Holdings Limited (SEHK:577). Dr. Lo is also the Founding Governor of the Charles K. Kao Foundation for Alzheimer’s Disease and the ISF Academy, and is also the present Chairman of Junior Achievement HK. Recently, Dr. Lo became a member of the Cyberport Advisory Panel and a member of the Hospital Governing Committee of the Hong Kong Red Cross Blood Transfusion Service. Dr. Lo is the Advisory Committee member of Chinese Medicine of Hong Kong Baptist University and an Advisory of Our Hong Kong Foundation. Dr. Lo has also been tasked by the United Nations ESCAP to lead a task force for the Sustainable Business Network’s to look at financial inclusion leveraging Fintech in the region. In 1998 Dr. Lo was appointed as a Hong Kong Justice of the Peace. From 2003 to 2016 he was appointed as a Committee Member of Shantou People’s Political Consultative Conference.
Wing Yan Lo,自2003年7月起担任董事会成员,并担任薪酬委员会和提名/公司治理委员会主席以及审计委员会主席。Lo博士是TMT(技术,媒体和电信)和消费领域的资深管理人员。他曾在中国联通,香港电信,香港花旗银行、I.T. Limited和South China Media Group等公司担任高级职位。他目前是SMI Holdings Group Ltd.(香港联交所股票代码:0198)的执行主席,该集团是中国最大的电影和新零售连锁店之一。他还是Captcha Media Ltd.(一家数字营销和战略机构)的主席,以及新的零售咨询平台OtoO Academy Limited&Strategenes Limited,一家香港的金融和战略咨询公司的主席。Lo博士毕业于剑桥大学,获得了硕士学位,药理学学位和80年代分子神经科学博士学位。Lo博士目前担任多家香港上市公司的独立非执行董事,包括Television Broadcasts Ltd.(香港联交所股票代码:511),CSI Properties Ltd.(香港联交所股票代码:497),SITC International Limited(香港联合交易所代码: 1308),Jing Rui Holdings Limited(香港联交所股票代码:1862),Ronshine China Holdings Limited(香港联交所股票代码:3301)及Hsin Chong Group Holdings Limited(香港联交所股票代码:0404)。Lo博士还是Charles K. Kao阿尔茨海默病基金会和ISF学院的创始理事,以及现任青年成就香港分会主席。Lo博士现为数码港顾问小组成员及香港红十字会输血服务医院管理委员会成员。1998年,Lo博士被任命为香港和平大法官。2003年至2016年,他被任命为汕头市人民政治协商会议委员。Lo博士目前担任提名/公司治理委员会和薪酬委员会主席。
Wing Yan Lo has served on our Board of Directors since July 2003 and is the chairman of our compensation committee and nominating and corporate governance committee. Dr. Lo is an experienced executive in the TMT technology, media and telecommunications and consumer sectors. He has previously held senior positions at China Unicom, Hongkong Telecom, Citibank HK, I.T. Limited, South China Media Group and Kidsland International Holdings Limited. He is currently the chairman of Captcha Media Ltd., a digital marketing and strategy agency. Dr. Lo graduated from Cambridge University with a M.Phil. degree in Pharmacology and a Ph.D. degree in Molecular Neuroscience in the 80’s. Dr. Lo currently serves as an independent non-executive director of a number of publicly listed companies in Hong Kong, including Television Broadcasts Ltd. (SEHK: 511), CSI Properties Ltd. (SEHK: 497), Jing Rui Holdings Limited (SEHK:1862) and South Shore Holdings Limited (SEHK:577). Dr. Lo is also the Founding Governor of the Charles K. Kao Foundation for Alzheimer’s Disease and the ISF Academy, and is also the present Chairman of Junior Achievement HK. Recently, Dr. Lo became a member of the Cyberport Advisory Panel and a member of the Hospital Governing Committee of the Hong Kong Red Cross Blood Transfusion Service. Dr. Lo is the Advisory Committee member of Chinese Medicine of Hong Kong Baptist University and an Advisory of Our Hong Kong Foundation. Dr. Lo has also been tasked by the United Nations ESCAP to lead a task force for the Sustainable Business Network’s to look at financial inclusion leveraging Fintech in the region. In 1998 Dr. Lo was appointed as a Hong Kong Justice of the Peace. From 2003 to 2016 he was appointed as a Committee Member of Shantou People’s Political Consultative Conference.
Mark Waslen

Mark Waslen, 自2003年7月成为公司董事,现任审计委员会主席、薪酬委员会和提名以及管制委员会成员。从1990年到1995年以及从1998年6月到1999年10月,他在南太担任多个职位,包括财务总监、秘书和风险官。自2010年6月1日起,他担任MNP 公司(加拿大特许会计师和商业咨询公司)合伙人;从2001年到2010年,他在Berris Mangan特许会计师 事务所(位于温哥华一家会计师事务所)工作。加入Berris Mangan之前,他曾被多个别的会计师事务所聘用,包括毕马域会计师索恩和德勤会计师事务所。他是一个注册金融分析师、总会计师以及注册会计师;他1982年毕业于萨斯喀彻温大学,持有商务会计专业学士学位。


Mark Waslen has served on our Board of Directors since July 2003 and is a member of our audit committee. From 1990 to 1995 and from June 1998 to October 1999 Mr. Waslen was employed by Nam Tai in various capacities, including financial controller, secretary and treasurer. Since June 1 2010 Mr. Waslen has been employed as a partner with MNP, a Canadian Chartered Accountant and business advisory firm. From 2001 to 2010 Mr. Waslen was employed by Berris Mangan Chartered Accountants, an accounting firm located in Vancouver, BC. Prior to joining Berris Mangan, Mr. Waslen worked at various other accounting firms, including Peat Marwick Thorne and Deloitte & Touche. Mr. Waslen is a CFA, CA and a CPA and received a Bachelor’s of Commerce Accounting Major from University of Saskatchewan in 1982.
Mark Waslen, 自2003年7月成为公司董事,现任审计委员会主席、薪酬委员会和提名以及管制委员会成员。从1990年到1995年以及从1998年6月到1999年10月,他在南太担任多个职位,包括财务总监、秘书和风险官。自2010年6月1日起,他担任MNP 公司(加拿大特许会计师和商业咨询公司)合伙人;从2001年到2010年,他在Berris Mangan特许会计师 事务所(位于温哥华一家会计师事务所)工作。加入Berris Mangan之前,他曾被多个别的会计师事务所聘用,包括毕马域会计师索恩和德勤会计师事务所。他是一个注册金融分析师、总会计师以及注册会计师;他1982年毕业于萨斯喀彻温大学,持有商务会计专业学士学位。
Mark Waslen has served on our Board of Directors since July 2003 and is a member of our audit committee. From 1990 to 1995 and from June 1998 to October 1999 Mr. Waslen was employed by Nam Tai in various capacities, including financial controller, secretary and treasurer. Since June 1 2010 Mr. Waslen has been employed as a partner with MNP, a Canadian Chartered Accountant and business advisory firm. From 2001 to 2010 Mr. Waslen was employed by Berris Mangan Chartered Accountants, an accounting firm located in Vancouver, BC. Prior to joining Berris Mangan, Mr. Waslen worked at various other accounting firms, including Peat Marwick Thorne and Deloitte & Touche. Mr. Waslen is a CFA, CA and a CPA and received a Bachelor’s of Commerce Accounting Major from University of Saskatchewan in 1982.

高管简历

中英对照 |  中文 |  英文
Jiabiao Wang

Jiabiao Wang于2019年2月被任命为中国运营总经理,负责中国项目的整体运营管理。他还曾担任深圳市房地产协会房屋租赁委员会副主任。


Jiabiao Wang于2019年2月被任命为中国运营总经理,负责中国项目的整体运营管理。他还曾担任深圳市房地产协会房屋租赁委员会副主任。
Jiabiao Wang has served as our chief executive officer since September 2020. Prior to his current position, he has served as the General Manager of China Operations from February 2019 responsible for the overall management of the project portfolio in China. He also served as the Deputy Director of the Shenzhen Real Estate Association Housing Rental Committee. Mr. Wang has more than 16 years of experience in real estate development and has extensive experience in marketing, investment and industrial operation management. Before joining Nam Tai, he was President of Kaisa Technology Innovation Group, a subsidiary of Kaisa Group 1638.HK. Prior to that, Mr. Wang served as Deputy General Manager of Logan Group Shenzhen, a subsidiary of Logan Group (03380.HK). Prior to that, Mr. Wang served as Assistant President of Kaisa Group Shenzhen. He also held senior executive positions with other leading Chinese property developers, including Shenzhen Huaqiang New City and Gemdale Corporation (600383.SH).
Terrence Lu

Terrence Lu在战略规划、投资和融资方面有着丰富的经验。他以前的工作经历包括著名的房地产公司和渣打银行深圳分行。


Terrence Lu在战略规划、投资和融资方面有着丰富的经验。他以前的工作经历包括著名的房地产公司和渣打银行深圳分行。
Terrence Lu has served as our chief financial officer since March 2021. Mr. Lu has extensive experience in strategic planning, investment and financing. Prior to joining us, Mr. Lu has held senior managerial roles at reputable real estate companies. He has also worked as a Senior Relationship Manager at Standard Chartered Bank, Shenzhen Branch. Mr. Lu received his bachelor’s degree in English from Jilin University Zhuhai College.